CanSino Biologics (HKG:6185, SHA:688185) will receive a further $17 million grant from Bill & Melinda Gates Foundation for the continued development of the recombinant poliomyelitis vaccine (CS-2036), a Wednesday bourse filing said.
The Chinese biotechnology firm had initially obtained $2 million of funding from the foundation in October 2023.
The further development included clinical research, process development and scale-up, and the development of CS-2036 component combined vaccine candidates
Shares of the company closed over 8% lower on Wednesday.
Price (HKD): $26.10, Change: $-2.3, Percent Change: -8.10%